design: RNA-seq of human colonic cancer cell line CACO-2 transfected 48h with siRNA targeting JAK1 (HJ1D8; HJ1D2) or JAK3 (HJ3D41; HMJ3D1) at 100pM final concentration using LipofectamineRNAiMAX or treated 48h with Tofacitinib (final concentration: 1µM) or Filgotinib (final concentration: 5µM) against controls (transfection medium: Opti-MEM, transfection mixt alone: Opti-MEM + Lipof., siMock, DMSO equivalent to volume added for Filgo 5µM).